NYLIM
KPTI icon

New York Life Investment Management’s Karyopharm Therapeutics KPTI Stock Holding History

New York Life Investment Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-5,131
Closed -$262K – 1303
2022
Q4 		$262K Buy
5,131
+578
+13% +$40.1K ﹤0.01% 1143
2022
Q3 		$373K Buy
4,553
+335
+8% +$25K ﹤0.01% 996
2022
Q2 		$285K Buy
+4,218
New +$387K ﹤0.01% 1168

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

New York Life Investment Management's KPTI Position: Q1 2023 in Review

New York Life Investment Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2023, closing a stake of 5,131 shares — an estimated $262K sold.

New York Life Investment Management first reported a position in KPTI in Q2 2022 and held it in 3 quarters. The position peaked at $373K in Q3 2022. 129 funds tracked by Wall St. Rank hold KPTI as of Q1 2023.

  • New York Life Investment Management reported no remaining Karyopharm Therapeutics position as of Q1 2023 after selling out during the quarter.
  • New York Life Investment Management sold 5,131 Karyopharm Therapeutics shares in Q1 2023, an estimated $262K.
  • New York Life Investment Management first reported a position in Karyopharm Therapeutics in Q2 2022 and held it in 3 quarters.
  • New York Life Investment Management's Karyopharm Therapeutics position peaked at $373K in Q3 2022.
  • 129 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2023.

Based on New York Life Investment Management's 13F filing for Q1 2023, filed 8 May 2023.